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Reverse Compliment, 40bp Oligonucleotides       Contains 
______________________________________________________________________________________ 
1. gcCTCGAGgtct agcaggtctgcgtcttcgggtcctccag                              1.XhoI Restriction Site 
Figure 5: Oligonucleotides used for PCR‐directed gene synthesis, forward and reverse complement. 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The following PCR protocol was used: |95°C, 4min (denature), 1x| [95°C, 30sec] [55°C, 30sec] 
[72°C, 45sec], 25x| 72°C, 4min, 1x| 10°C, ∞|. The PCR products were separated using agarose 
gel electrophoresis using TAE (0.04M Tris‐HCl, 1 mM EDTA, 57.2μL glacial acetic acid) and 9% 
agarose gel. The products were purified from the agarose gel using a Promega Wizard PCR 
Preps DNA Purification System (cat. #A7170).  
 
Molecular Cloning 
The PCR products were cloned into a Promega pGEM‐T Vector (cat. # A362A) following 
the standard protocol. Chemically competent DH5α E. coli were chemically transformed with 
the ligated T‐vector. Cultures were grown on agar plates containing 0.1 mg/mL ampicillin plates 
with 40μg/mL x‐gal, and 0.1mM IPTG overnight at 37°C. White colonies were selected and 3mL 
of media was inoculated with each selected culture. These were allowed to incubate overnight. 
Plasmid DNA was purified according to standard alkaline lysis protocols (0.2%N NaOH, 1% SDS). 
Chemically competent DH5α E. coli were transformed with the purified plasmid DNA and 
incubated in 100mL of LB media overnight with shaking. Plasmid DNA was purified using 
Promega Wizard Midipreps DNA Purification System (cat #A7640). The gene insert was cut out 
of the T‐vector using restriction digest with BamHI and EcoRI for the pGBKT7 insert or BamHI 
and XhoI for the pACT2 insert. Restriction digests were performed on the Clonetech pGBKT7 
vector (cat #K1612‐1) and the pACT2 vector (cat #K1604‐A) using BamHI and EcoRI for pGBKT7 
vector, and BamHI and XhoI for pACT2 vector. The vectors were purified from 0.9% agarose gel 
using MP Biomedical’s GeneClean Kit (cat. # 1001‐200).  
  19 
 
 
Figure 6: Overall molecular cloning strategy for creating a construct to assess multimerization. We have created two T‐Vector 
constructs with our TTV VP3 insert. The steps following are for the creation of two final constructs for use in a yeast 2‐hybrid 
system to continue multimerization analysis.  
Cell Culture and Apoptosis Assay 
H1299 cells were maintained in culture using DMEM + 10% FBS with 1x PSF. The cells 
were passed regularly before reaching complete confluency. For the apoptosis assay, H1299 
lung carcinoma cells were passed into a 96 well plate at a concentration necessary to obtain 
70% confluency within 1‐2 days. The cells were then transfected with Apoptin as a positive 
control and Human TTV VP3, both in Flag vector constructs using the Effectene Transfection 
Reagent. The cultures were allowed to incubate for 24 hours at 37°C. After 24hours, the media 
was removed, the cells were washed with PBS, and 50μL of media was added back to the cells. 
An Apo‐One Homogeneous Caspase‐3/7 Assay kit was used to determine whether or not 
Apoptin and TTV VP3 had the ability to induce apoptosis along the caspase 3/7 pathway. 50μL 
of substrate was added to each well as prescribed by the assay. The cells were allowed to 
incubate for 18 hours at room temperature in the dark.  Fluorescence readings were taken at λ 
ex 499nm and λ em521nm and verified that Apoptin and TTV VP3 induces apoptosis in H1299 
cells. 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Results  
Sequence Analysis of TTV VP3 Compared to Apoptin 
As TTV VP3 has not been fully characterized or studied extensively, a comparison to a 
better‐known homolog was essential for this study. More work has been done to identify 
important sequences within the third open reading frame (ORF3) of CAV, which encodes for 
Apoptin. 
The Chicken Anemia Virus protein Apoptin has been shown to selectively induce 
apoptosis in transformed cells but not primary cells. Two characteristics of the protein are 
thought to contribute to this selectivity. The first is the protein's localization within transformed 
cells compared to primary cells. In transformed cells Apoptin migrates into the nucleus, 
whereas in primary cells it is retained mainly within the cytoplasm. The second characteristic of 
the protein, which may play a role in Apoptin’s cancer killing ability, is multimerization. It has 
been shown that Apoptin spontaneously forms 30 to 40 subunit multimers in vivo. The area 
responsible for multimerization overlaps with the Nuclear Export Sequence (NES) (aa 33‐46), in 
which hydrophobic and hydrophilic residues alternate. Leliveld et al. (2003) determined the 
amino acids 32‐46 may fold with the amino acids 38 and 39 as an anti‐parallel beta sheet in 
hairpin orientation. In this case, the hydrophobic residues would be facing towards each other, 
while the hydrophilic residues would be protruding outwards in the opposite direction. This 
structural motif is hypothesized to account for Apoptin's ability to multimerize, perhaps by Ile 
and Leu residues interlocking between Apoptin monomers to form Apoptin multimers. 
  Similarly, TTV VP3 has significant cellular localization and multimerization properties 
that may be important in its cancer killing ability. Localization of TTV VP3‐GFP in vivo has been 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shown to be largely time dependent. After twenty‐four hours in cancerous cells, the protein 
was found in both the nucleus and the cytoplasm. When examined at forty‐eight hours the 
protein was found to be localized almost exclusively in the cytoplasm, largely in punctate foci at 
the nuclear and cytoplasmic periphery. Significantly, this shows that TTV VP3 may have a 
functional NLS and NES. Because the area responsible for multimerization in Apoptin overlaps 
with the NES, a comparative sequence analysis of with TTV VP3 was performed. 
In order to perform this sequence analysis, the known, published sequences of Apoptin 
and TTV VP3 along with CLC workbench were used to perform the alignment. The data from 
this study can be found in Figure 7. The amino acids appear for each sequence and are color‐
coded based on hydrophobicity and charge. Black amino acids are hydrophobic while green are 
hydrophilic. Blue amino acids are hydrophilic and positively charged while red are hydrophilic 
and negatively charged. An exact amino acid match is indicated by the red regions below the 
amino acid residues. Interestingly, in aligning the two sequences and examining the NES and 
Multimerization domain in Apoptin’s sequence, it was observed that the residues (AA 33‐46) 
alternate between hydrophobic and hydrophilic residues while in TTV VP3’s (aa 24‐39) they are 
all hydrophobic. This could suggest possible structural and functional differences between the 
two proteins. Despite this difference, it is important to note that all the proline residues in the 
two sequences were aligned suggesting possible structural similarity as proline produces a 
distinctive kink in a polypeptide chain. Leliveld et al. predicted that it was Apoptin's canonical 
sequence that gave it the necessary conformation to form multimers. TTV VP3's difference in 
structure could have several implications in its cancer killing mechanism and evolutionary 
divergence from Apoptin. 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PCR and Molecular Cloning 
As multimerization was thought to be an important part of Apoptin’s mechanism for 
selectively inducing apoptosis in transformed cells, further examination as to whether or not 
TTV VP3 also had the capability to multimerize was performed. One way of determining if VP3 
can multimerize is to use a yeast 2‐hybrid system. This experiment utilizes the internal 
mechanisms of a yeast genome, in that if the Gal4 upstream activating sequence is turned on 
by a particular transcription factor it will activate the LacZ gene. This gene encodes the enzyme 
Beta Galactosidase, which can metabolize X‐Gal, a substance introduced experimentally. This 
will produce a blue dye, which can allow for phenotypic selection of colonies of yeast that have 
the transcription factor for Gal4. To test for multimerization, the transcription factor is divided 
into two parts; the Gal4 binding domain contained on our pGBKT7 vector, and a Gal4 activating 
domain contained in the pACT2 vector. Should the TTV VP3 protein be present in both these 
vectors, expressed within the cells, and multimerize with each other they will bring the 
transcription factors back into close proximity with each other and activate the LacZ gene. 
Before this can be performed, constructs must be made of the VP3 and inserted into the 
appropriate vectors. As two different terminal vectors are used in this experiment and contain 
different restriction sites, two separate constructs had to be designed and synthesized. In order 
to do this, two sets of primers that included the appropriate restriction sites for each vector 
were constructed. After PCR was performed using the VP3 template that was synthesized by E. 
Evan‐Browning and M. Orme‐Johnson last year, the purified products were run on an agarose 
gel to confirm the product. This gel is shown in figure 8A. Lane 1 contains the molecular weight 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marker. In lanes 2 and 3, the two purified PCR products can easily be seen as bright bands near 
the bottom of the gel. Lane 2 contains the purified product for the pACT2 vector. Lane 3 
contains the purified product for the pGBKT7 vector. With the two PCR products purified and 
confirmed, the next step was to ligate them into T‐vectors. The T‐vectors serve as a useful 
stable cloning intermediate that can be transformed into E. coli to increase insert copy number. 
Once the insert is ligated into a T‐vector, it must be restricted out and purified, then it can be 
ligated into the terminal pACT2 and pGBKT7 vectors for the yeast 2‐hybrid assay. Performing 
the restriction digest and running the products on a gel is a useful way to confirm that the 
insert was successfully ligated into the T‐vector. Figures 8B and 8C shows the gels that were run 
of the restriction digests to verify that the insert had been ligated into the vector. Lane 1 in 
each is a molecular weight marker while lane two contains the samples. The upper band on 
both gels shows the empty restricted vector (pACT2 in B and pGBKT7 in C) while the lower faint 
band is that of the restricted insert that has been successfully cleaved from the vector. To 
additionally confirm that the constructs contained the appropriate inserts, samples of each 
were sent out for sequence analysis and results are pending. Once confirmed by sequence 
analysis, ligation of the inserts into the pACT2 and pGBKT7 vectors can be performed along with 
the multimerization analysis via a yeast 2‐hybrid assay. 
Apoptosis Assay 
In parallel with our study, apoptosis experiments to examine TTV VP3’s ability to 
selectively induce apoptosis in transformed cells were performed. In order to perform these 
experiments, Flag constructs of TTV VP3 and native Apoptin were transfected into H1299 cells 
in a 96 well plate. The Apoptin served as a positive control.  Cells and media that were taken 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through the transfection process without DNA served as a negative control. Apo‐One 
Homogeneous Caspase‐3/7 Assay kit was used to determine whether or not TTV VP3 had the 
ability to induce apoptosis along the caspase 3/7 pathway. This kit contains a substrate, which 
is cleaved and fluoresces if the caspase 3/7 pathway is activated. After an 18‐hour incubation at 
room temperature in the dark, fluorescence readings were taken of each of the samples. A λ ex 
499nm and λ em521nm were used to scan the samples over a range of 510‐547nm. Figure 9A is 
a graph of the curves generated by each of the samples. The x‐axis shows the nm range the 
samples were scanned along while the y‐axis is a measure of relative fluorescence units (rFU). 
The negative controls showed only baseline levels of apoptosis and the curves for each are 
clustered on the lower portion of the graph and show no peak at 521nm. Visually, when 
observed under a microscope, the cells remained healthy with very low levels of cell death. The 
cells transfected with Apoptin and TTV VP3, when inspected visually showed very high levels of 
apoptosis with cell debris comprising the majority of each well. In Figure 9A, it can be observed 
that the curves for Apoptin and TTV VP3 are interspersed in a fairly tight range. Each curve 
exhibits a peak at 521nm, which is expected for this assay if apoptosis was induced.  The rFU 
values for Apoptin and TTV VP3 were much higher than that of the negative controls as well. 
This confirmed that both Apoptin and TTV VP3 induced apoptosis in the H1299 cells through a 
caspase 3/7 dependent pathway. Interestingly, not only did TTV VP3 also induce apoptosis in 
the H1299 cells, but the levels of apoptosis were similar to that caused by the positive control 
Apoptin. In Figure 9B, the averages of the three samples for each the negative control, positive 
control (Apoptin), and TTV VP3 were taken and plotted in a bar graph. In this graphical 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representation, it is easy to see that Apoptin and TTV VP3 induced apoptosis at similar levels 
significantly higher than those seen by the baseline shown by the negative control. 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Discussion and Future Experiments 
Sequence analysis of TTV and Apoptin 
  TTV VP3 is considered a homolog to the Chicken Anemia Virus Apoptin; a protein 
capable of inducing apoptosis selectively in cancerous and transformed cells. Though the 
mechanism by which it accomplishes this is largely unknown, its nuclear localization [34] as well 
as its ability to multimerize with itself has been shown to be essential in its apoptotic capability. 
By performing a sequence analysis of TTV VP3 and Apoptin we have found that the mechanism 
of multimerization, and possibly apoptosis, may be significantly different.  
Apoptin’s nuclear localization was originally thought to be required because it is 
localized in the nucleus in all cancer cells and is thought to target subunit 1 of the anaphase 
promoting complex/cyclosome (APC/C) while it is in the nucleus [35]. The APC is a master 
regulator of the cell cycle and is also responsible for several important checkpoints during 
mitosis. One of its most important activities is the transition from metaphase to anaphase, as 
its name suggests. It performs this action by separation of sister chromatids once all of the 
mitotic spindles have attached to the kinetichores. If even one spindle is not connected this 
pathway will shut down. Such a sensitive and important pathway is therefore a very attractive 
target for a viral protein. The only problem with this theory is that Apoptin’s entry into the 
nucleus causes cell cycle arrest at G2/M phase, followed by apoptosis; yet, there is no nucleus 
at this point of the cell cycle. Therefore it may be possible that the localization sequence is not 
necessary to gain access to the nucleus, however studies have shown that its presence is 
required for apoptosis. 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When the sequence analysis of Apoptin is compared with that of TTV VP3 the 
alternating hydrophobic‐hydrophilic residue sequence of Apoptin’s multimerization domain is 
not seen in TTV. This is significant because the way in which Apoptin multimerizes has been 
shown to affect its ability to induce apoptosis. This suggests that perhaps TTV VP3 A) does not 
multimerize, or B) multimerizes in a manner different than Apoptin. Should the former be true, 
it may support the idea that Apoptin multimerizes as an alpha helix, with its hydrophilic 
residues protruding outside and its hydrophobic residues inside. This would mean that because 
of TTV VP3’s only hydrophobic residues at Apoptin’s area of multimerization TTV VP3 does not 
undergo multimerization. However, if TTV VP3 did undergo multimerization its possible that it 
does in fact induce apoptosis independent of nuclear APC/C, and therefore may not need to be 
in the nucleus to induce apoptosis. In either situation, the incongruity of amino acid sequence 
may provide valuable insight into the apoptotic pathways for both of these viral proteins, as 
well as the role multimerization and nuclear proteins play in TTV VP3. 
Interestingly, when the sequence for nuclear localization in Apoptin is compared to that 
of TTV VP3 they again differ. The canonical bipartite nuclear localization sequence, typically 
made of leucine and arginine amino acids, are found in Apoptin is made of KKR (amino acids 86‐
88) and KRR (amino acids 115‐117) which are polar hydrophilic amino acids. When compared to 
the TTV VP3 sequence the only sequence matched up is EHH (amino acids 86‐88), which are 
hydrophilic and polar but do not fit the bipartite sequence expected of nuclear localization. This 
evidence favors the theory that nuclear localization is not a necessary part of inducing 
apoptosis in. Instead, this begs the question as to what part of Apoptin’s NLS are playing a part 
in its apoptotic ability.  
  28 
Despite the sequential differences seen in many of Apoptin’s well‐characterized 
sequence, there are some similarities. The most striking of these is the overlapping proline 
residues in five disparate areas corresponding to Apoptin’s amino acids 20, 58, 84, 96, and 116. 
Proline has a distinct cyclic structure, which gives it a very strong rigidity that forms into a kink 
on a peptide chain. Because these groups are highly conserved in both viruses suggests that 
they still may share a similar 3‐D orientation and functionality. Much effort has been put into 
examining Apoptin’s nuclear import and export sequences as well as localization within the cell, 
but without a nucleus during the phase in which Apoptin arrests the cell it is difficult to know 
the exact importance these have on inducing apoptosis. Therefore finding conserved residues 
between the two homologous viruses may aid in future studies.  
Apoptosis Study 
  In parallel with the comparative sequence analysis, the apoptotic capability of TTV VP3 
was determined. Prior to our experiments only one experiment, performed by Noteborn et al, 
showed putative cancer killing ability. The shortcomings of this experiment were that the data 
was qualitative and showed no discernable pathway or mechanism by which TTV VP3 was 
inducing apoptosis. Therefore it was critical that we provide a concrete quantitative experiment 
that followed a specific mechanism. The apoptosis study performed in H1299 (human lung 
carcinoma) cells showed that TTV can induce apoptosis in H1299 cells through a specific 
caspase 3/7 dependent pathway. Visually, noticeable levels of apoptosis were observed in the 
TTV and Apoptin (+CTRL) samples 24hrs after the transfections. When the fluorescence 
readings were taken at 521nm after an additional 18‐hour incubation, TTV VP3 and Apoptin 
were shown to induce apoptosis at similar levels. Both of these samples were significantly 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higher than the negative control that was only cells in media.  In the two trials performed, we 
used six samples for each. Results were reproducible and consistent within the trial and within 
the two that were performed as well showing low variability. We attribute the variability of this 
assay due to the unknown transformation efficiencies within the individual wells as well as the 
rate of substrate cleavage. This study can be used as a starting point for further experiments to 
explore TTV VP3’s apoptosis inducing ability more in depth.  To continue this study, we 
recommend repeating this assay as a time course over 18 hours, taking fluorescence readings 
every hour for 18 hours. In addition, we recommend performing this same experiment using 
primary cells to ensure that TTV VP3 is selectively inducing apoptosis in transformed cells only. 
Yeast 2­Hybrid Multimerization Experiments  
Multimerization has clearly been a topic of great interest among those studying Apoptin 
and its homologs. Whether or not TTV VP3 in fact does undergo multimerization has yet to be 
definitively determined. What is important is that both TTV VP3 and Apoptin are capable of 
inducing apoptosis via a caspase 3/7 pathway. Therefore the molecular cloning performed 
should be continued into further its final stage; the Yeast 2‐hybrid assay. Using the T‐vector 
constructs, the TTV VP3 inserts should be restricted out and ligated into the pACT2 and pGBKT7 
vectors. A Yeast 2‐Hybrid assay can then be performed to determine whether VP3 has the 
ability to multimerize with itself. If the result of this assay confirms the ability for 
multimerization, a few experiments should be done to further explore its importance. First, the 
multimerization domain should be identified and a knockout mutant of the multimerization 
domain should be created. Using this knockout mutant, the apoptosis experiment performed in 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this study should be repeated to determine multimerization’s role in inducing apoptosis in 
transformed cells. 
If it is found that TTV VP3 does not have the ability to multimerize with itself, then the 
question becomes what is the cause of the selective induction of apoptosis in transformed cells 
but not primary cells. If multimerization is not a part of VP3’s apoptosis inducing pathway, 
there must be some other factor such as another protein specific to transformed cells it is 
interacting with. Multimerization is thought to be a regulatory factor in Apoptin in that in 
primary cells it is seen as insoluble aggregates that cannot induce apoptosis while in 
transformed cells the multimers are smaller and soluble allowing for apoptosis induction. 
Without this mechanism of regulation in TTV VP3, another protein could be acting to inhibit and 
inactivate it from inducing apoptosis. Another possibility is that the differences in primary and 
transformed cell environments can contribute to the activation or inactivation of TTV VP3. 
Although these two scenarios are possible, it is unlikely that TTV VP3 does not multimerize as it 
exhibits similar punctate cellular localization patterns to that of Apoptin, which has been shown 
to multimerize. 
Localization Experiments 
An additional experiment that should be conducted is further analysis into the 
localization of TTV VP3 in transformed and primary cells. Preliminary data has shown that in 
transformed cells TTV VP3 will localize primarily in the cytoplasm and appear in a punctate 
pattern along the nuclear periphery. By performing localization experiments in primary cells, 
meaningful data can be collected as to its preferred location in transformed cells as opposed to 
primary cells, as well as the area in which it is present during apoptosis. Additionally, it may be 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interesting to locate the Nuclear Localization and Nuclear Export Sequences. Once this is done, 
knockout mutants of each of these can be created for further analysis of nuclear‐cytoplasmic 
shuttling. 
Structural Analysis 
In order to fully understand how the multimerization domain, NLS, and NES interact, the 
crystal structure of TTV VP3 must be discovered. Before attempting to crystallize VP3, it may be 
useful to perform Circular Dichroism to analyze the secondary and tertiary structures of the 
protein. This can provide valuable information about the flexibility of the protein that can aid in 
developing a crystallization strategy. Once the crystal structure is obtained, experiments can be 
devised to explore the interaction of VP3’s domains with other proteins and itself. This can help 
to provide information about the pathways involved in VP3’s apoptosis inducing ability. In 
addition, knowledge of the crystal structure can help with determining how VP3 changes in 
primary cell versus transformed cell environments. This may also help to provide insight into 
VP3’s mechanism of action. 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Conclusion 
The human Torque Teno Virus is a largely unstudied virus. TTV is thought to be 
homologous to the Chicken Anemia Virus, which is a very well characterized virus, and 
therefore meaningful comparisons can be drawn from analysis of the two. As mentioned in the 
discussion of multimerization, the mechanism by which Apoptin and TTV VP3 induce apoptosis 
may be different. The sequence analysis showed that TTV VP3 may multimerize differently than 
Apoptin, if at all, and preliminary localization studies show that at 48 hours TTV VP3 does not 
even appear in the nucleus of a transformed cell, whereas Apoptin has been shown to recruit 
nuclear proteins in order to induce apoptosis. An interesting result of this apoptosis assay is 
that both Apoptin and TTV VP3 use a very specific caspase 3/7 dependent pathway in order to 
induce apoptosis in H1299 cancerous cells. Therefore the apoptotic result is the same, yet the 
mechanism by which apoptosis induces the caspase pathway is still to be determined in future 
experiments. The implications of these studies of Apoptin and TTV VP3 to cancer research  as a 
whole is very exciting. If the specific pathways involved in targeting cancer cells and selectively 
inducing apoptosis can be discovered and characterized, potential therapeutics can be designed 
to mimic this mechanism. 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Figures: 
 
 
Figure 7: Sequence Analysis of TTV VP3 and CAV VP3. Black amino acids are hydrophobic. Green amino acids are hydrophilic. 
Blue amino acids are hydrophilic and + charged. Red amino acids are hydrophilic and – charged.  An exact amino acid match 
is shown by the red regions below the amino acid residues. 
 
 
Figure 8: (A) Agarose gel of PCR products. Lane 1 contains the Molecular Weight Marker. Lane 2 contains the TTV VP3 
product from the primers designed for the pACT2 vector. Lane 3 contains the TTV VP3 product from the primers designed for 
the pGBKT7 vector. (B) Agarose gel of restricted T‐Vector with TTV VP3 Dropouts. Lane 1 contains a Molecular Weight 
Marker. Lane 2 shows the Bam HI and XhoI restricted T‐vector in the top band and the TTV VP3 pACT2 insert in the bottom 
band. (C) Agarose gel of restricted T‐Vector with TTV VP3 Dropout. Lane 1 contains a Molecular Weight Marker. Lane 2 shows 
the BamHI and EcoRI restricted T‐vector in the top band and the TTV VP3 pGBKT7 insert in the bottom band. 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Figure 9: (A) Apoptosis Assay Curves for + Control, ‐Control, and TTV samples. Apoptosis is the result of the activation of 
caspase 3/7, which results in a cleavage of the fluorescent substrate. Fluorescence readings were taken at 521nm. (B) 
Quantified averaged data from Apoptosis Assay of the samples. Negative CTRL (cells and media only) showed baseline 
apoptosis. Positive CTRL (Apoptin) set the bar for apoptosis level. TTV samples were all in the range (or higher than + CTRL) 
rFU 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